Business Context and Reporting Period
Company: Ares Capital Corporation (ARCC)
Filing Type: Form 8-K (Current Report)
Date: November 8, 2019
Event: Entry into Material Definitive Agreements for equity distribution.
Key Financial Metrics
This filing does not report specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the authorization of a potential equity offering.
Material Changes and Agreements
- Equity Distribution Agreements: Entered into separate agreements with SunTrust Robinson Humphrey, Inc. and Capital One Securities, Inc.
- Offering Capacity: Authorization to issue and sell shares of common stock with an aggregate offering price of up to $500,000,000.
- Sale Method: Shares may be sold in negotiated transactions or "at the market" transactions (Rule 415(a)(4)), including direct sales on the NASDAQ Global Select Market.
- Compensation: Sales Agents will receive a commission of up to 1.5% of the gross sales price of shares sold.
- Obligation: The Company has no obligation to sell any shares and may suspend the offering at any time based on market conditions and capital needs.
Guidance, Outlook, and Risks
Management Commentary: Actual sales depend on market conditions, the trading price of the Company's common stock, and determinations regarding the need for additional capital.
Risks/Contingencies: The filing notes that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful prior to registration. The offering is subject to customary representations, warranties, and termination provisions.
Investor Verification Checklist
- Verify the full text of the Equity Distribution Agreements (Exhibits 10.1 and 10.2) for specific termination rights and conditions.
- Monitor future filings to determine if and when shares are actually sold under this program.
- Review the Prospectus Supplement dated November 8, 2019, for detailed terms of the offering.
- Check subsequent 10-Q or 10-K filings for the impact of any share sales on dilution and capital structure.